中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

38 records (took 0.023 seconds)

    Erythropoietin conjugate
    1.
    发明专利
    Erythropoietin conjugate 有权
    红细胞凝集素

    公开(公告)号：JP2008069155A

    公开(公告)日：2008-03-27

    申请号：JP2007241171

    申请日：2007-09-18

    Applicant: F Hoffmann La Roche Ag ,  エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft

    Inventor： BURG JOSEF ,  ENGEL ALFRED ,  FRANZE REINHARD ,  HILGER BERND ,  SCHURIG HARTMUT ERNST ,  TISCHER WILHELM ,  WOZNY MANFRED

    IPC: C07K14/505 ,  C12P21/02 ,  A61K38/27 ,  A61K47/48 ,  A61P7/06 ,  A61P13/12 ,  A61P31/18 ,  A61P35/00 ,  C07K1/113 ,  C12N15/09 ,  C12R1/91

    CPC classification number: A61K47/62 ,  A61K47/60

    Abstract: PROBLEM TO BE SOLVED: To provide an erythropoietin/poly(ethylene)glycol conjugate comprising an erythropoietin glycoprotein having an N-terminal α-amino group and having the in vivo biological activity of causing bone marrow cells to increase the production of reticulocytes and erythrocytes and selected from the group consisting of human erythropoietin and analogues thereof which have the sequence of human erythropoietin modified by the addition of 1-6 glycosylation sites or a rearrangement of at least one glycosylation site. SOLUTION: The glycoprotein is one covalently linked to one poly(ethylene glycol) group represented by the formula: -CO-(CH 2 ) x -(OCH 2 CH 2 ) m -OR [wherein the -CO in the poly(ethylene glycol) group forms an amide bond with the N-terminal α-amino group; R is a lower alkyl; x is 2 or 3; and m is about 450 to about 1,350]. COPYRIGHT: (C)2008,JPO&INPIT

    Abstract translation: 待解决的问题：提供一种促红细胞生成素/聚（乙二醇）轭合物，其包含具有N-末端α-氨基的促红细胞生成素糖蛋白，并且具有引起骨髓细胞的体内生物活性以增加网织红细胞的产生 和选自人红细胞生成素及其类似物的组，其具有通过加入1-6个糖基化位点或至少一个糖基化位点的重排而修饰的促红细胞生成素序列。 解决方案：糖蛋白是共价连接到由下式表示的一个聚（乙二醇）基团：-CO-（CH 2 ） 其中聚（乙二醇）基团中的-CO与N-末端的α形成酰胺键， 氨基; R是低级烷基; x为2或3; m为约450至约1,350]。 版权所有（C）2008，JPO＆INPIT

    ACETYLATION OF GP41 FRAGMENTS
    2.
    发明申请
    ACETYLATION OF GP41 FRAGMENTS 审中-公开
    GP41片段的乙酰化

    公开(公告)号：WO02103026A2

    公开(公告)日：2002-12-27

    申请号：PCT/EP0205782

    申请日：2002-05-27

    Applicant: HOFFMANN LA ROCHE

    Inventor： HOESS EVA ,  MEIER THOMAS ,  PESTLIN GABRIELE ,  POPP FRIEDRICH ,  REICHERT KLAUS ,  SCHMUCK RAINER ,  SCHNEIDINGER BERND ,  SEIDEL CHRISTOPH ,  TISCHER WILHELM

    IPC: C12N15/09 ,  A61K38/00 ,  A61P31/12 ,  A61P31/18 ,  C07K14/155 ,  C07K14/16 ,  C12N1/21 ,  C12N15/62 ,  C12P21/02 ,  C12P21/00

    CPC classification number: C07K14/005 ,  C07K2319/00 ,  C12N2740/15022 ,  C12N2740/16122 ,  C12P21/02

    Abstract: A process for the production of an antifusogenic peptide of a length of about 10 to 50 amino acids in a prokaryotic host cell, characterized in that, under such conditions that inclusion bodies of said non-fusion antifusogenic peptide or said fusion peptide are formed, a) in said host cell there is expressed a nucleic acid encoding said antifusogenic peptide as a non-fusion peptide or encoding a fusion peptide of a length of about 14 to 70 amino acids consisting of said antifusogenic peptide N-terminally linked to a further peptide of a length of about 4 to 30 amino acids; b) said host cell is cultivated; c) said inclusion bodies are recovered and solubilized; d) in the case of said fusion peptide said antifusogenic peptide is cleaved off from said further peptide; and e) said antifusogenic peptide is isolated.

    Abstract translation: 一种在原核宿主细胞中生产长度约10至50个氨基酸的抗融合肽的方法，其特征在于，在形成所述非融合抗融合肽或所述融合肽的包涵体的条件下， ）在所述宿主细胞中表达编码所述抗融合肽作为非融合肽或编码长度约为14至70个氨基酸的融合肽的核酸，所述融合肽由所述抗融合肽组成，所述融合肽与N-末端连接的另一个肽 长度约4至30个氨基酸; b）培养宿主细胞; c）所述包涵体被回收和溶解; d）在所述融合肽的情况下，所述抗融合肽从所述另外的肽切除; 和e）分离所述抗融合肽。

    CONJUGATES OF ERYTHROPOIETIN (PEP) WITH POLYETHYLENE GLYCOL (PEG)
    3.
    发明申请
    CONJUGATES OF ERYTHROPOIETIN (PEP) WITH POLYETHYLENE GLYCOL (PEG) 审中-公开
    聚乙二醇（PEG）与聚乙二醇（PEG）的结合

    公开(公告)号：WO0249673A3

    公开(公告)日：2003-01-23

    申请号：PCT/EP0114434

    申请日：2001-12-08

    Applicant: HOFFMANN LA ROCHE

    Inventor： BURG JOSEF ,  ENGEL ALFRED ,  FRANZE REINHARD ,  HILGER BERND ,  SCHURIG HARTMUT ERNST ,  TISCHER WILHELM ,  WOZNY MANFRED

    IPC: A61K47/48 ,  A61K38/18 ,  C07K14/505

    CPC classification number: A61K47/62 ,  A61K47/60

    Abstract: The present invention refers to conjugates of erythropoietin with poly(ethylene glycol) comprising an erythropoietin glycoprotein having an N-terminal alpha -amino group and having the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to one poly(ethylene glycol) group of the formula -CO-(CH2)x-(OCH2CH2)m-OR with the -CO of the poly(ethylene glycol) group forming an amide bond with said N-terminal alpha -amino group; wherein R is lower alkyl; x is 2 or 3; and m is from about 450 to about 1350.

    Abstract translation: 本发明涉及促红细胞生成素与聚（乙二醇）的缀合物，其包含具有N-末端α-氨基的促红细胞生成素糖蛋白，具有引起骨髓细胞增加网织红细胞和红细胞产生的体内生物学活性， 由人促红细胞生成素及其类似物组成，其具有通过加入1至6个糖基化位点或至少一个糖基化位点的重排而修饰的人促红细胞生成素序列; 所述糖蛋白与式-CO-（CH2）x-（OCH2CH2）m-OR的一个聚（乙二醇）基团共价连接，聚（乙二醇）基团的-CO与所述N- 末端α-氨基; 其中R是低级烷基; x为2或3; m为约450至约1350。

    PEGYLATED AND DIGLYCOSYLATED ERYTHROPOIETIN
    4.
    发明申请
    PEGYLATED AND DIGLYCOSYLATED ERYTHROPOIETIN 审中-公开
    PEG化和DIGLYCOSYLATED红细胞生成素

    公开(公告)号：WO03029291A3

    公开(公告)日：2003-07-24

    申请号：PCT/EP0210556

    申请日：2002-09-20

    Applicant: HOFFMANN LA ROCHE

    Inventor： TISCHER WILHELM

    IPC: C12P21/02 ,  A61K38/00 ,  A61K38/22 ,  A61K47/48 ,  A61P7/06 ,  C07K14/505 ,  C12N15/12

    CPC classification number: C07K14/505 ,  A61K38/00 ,  A61K47/60 ,  Y10S514/814

    Abstract: The invention provides an erythropoietin mutein having the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells, characterized by being N-glycosylated at Asn38 but not N-glycosylated at Asn24. Such muteins have improved pharmaceutical properties.

    Abstract translation: 本发明提供了突变蛋白具有使骨髓细胞增加生产网织红细胞和血红细胞的的体内生物学活性促红细胞生成素，其特征在于处于Asn38的N-糖基化，但在Asn24不N-糖基化。 这种突变蛋白具有改善的药物性质。

    Erythropoietin conjugates
    7.
    发明专利
    Erythropoietin conjugates 未知

    公开(公告)号：AU3323002A

    公开(公告)日：2002-07-01

    申请号：AU3323002

    申请日：2001-12-08

    Applicant: HOFFMANN LA ROCHE

    Inventor： BURG JOSEF ,  ENGEL ALFRED ,  FRANZE REINHARD ,  HILGER BERND ,  SCHURIG HARTMUT ERNST ,  TISCHER WILHELM ,  WOZNY MANFRED

    IPC: C12P21/02 ,  A61K47/48 ,  A61P7/06 ,  A61P13/12 ,  A61P31/18 ,  A61P35/00 ,  C07K1/113 ,  C07K14/505

    Abstract: The present invention refers to conjugates of erythropoietin with poly(ethylene glycol) comprising an erythropoietin glycoprotein having an N-terminal alpha-amino group and having the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have the sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to one poly(ethylene glycol) group of the formula -CO-(CH 2 ) x -(OCH 2 CH 2 ) m -OR wherein the -CO of the poly(ethylene glycol) group forms an amide bond with said N-terminal alpha-amino group; and wherein R is lower alkyl; x is 2 or 3; and m is from about 450 to about 1350.

    CONJUGADOS DE COMPLEMENTO PEPTIDO.
    9.
    发明专利
    CONJUGADOS DE COMPLEMENTO PEPTIDO. 未知

    公开(公告)号：ES2374962T3

    公开(公告)日：2012-02-23

    申请号：ES08716417

    申请日：2008-03-11

    Applicant: HOFFMANN LA ROCHE

    Inventor： DUEFEL HARTMUT ,  FALKENSTEIN ROBERTO ,  LEIN IRIS ,  SCHMUCK RAINER ,  TISCHER WILHELM

    IPC: C07K14/16 ,  C07K14/47 ,  C12N15/62

    Abstract: Conjugado de polipéptidos, caracterizado porque dicho conjugado comprende: a) un primer polipéptido seleccionado de entre la subunidad A del factor del complemento humano C1q de SEC ID nº 01, b) un segundo polipéptido seleccionado de entre el grupo de péptidos antifusogénicos lineales que inhibe sucesos asociados a la fusión de membranas o el suceso mismo de fusión membranal, incluyendo, entre otras cosas, la inhibición de la infección por un virus de células no infectadas debido a la fusión membranal.

Patent Agency Ranking